Intangible assets
The carrying amount of intangible assets mainly comprises goodwill on the acquisition of NeoResins in 2005 (€358 million), Crina in 2006 (€8 million) and Pentapharm in 2007 (€34 million). For further information on these assets including the discussion of the related impairment tests, please refer to Note 8 Intangible assets in the 'Notes to the consolidated financial statements of Royal DSM'.
|
Goodwill
|
Under construction
|
Other
|
Total
|
|
|
Balance at 1 January 2017
|
||||
|---|---|---|---|---|
|
Cost
|
403
|
4
|
78
|
485
|
|
Amortization and impairment losses
|
-
|
-
|
38
|
38
|
|
Carrying amount
|
403
|
4
|
40
|
447
|
|
Change in carrying amount
|
||||
|
- Capital expenditure
|
-
|
1
|
-
|
1
|
|
- Put into operation
|
-
|
(4)
|
4
|
-
|
|
- Exchange difference
|
(4)
|
-
|
-
|
(4)
|
|
- Amortization
|
-
|
-
|
(8)
|
(8)
|
|
- Impairment losses
|
-
|
-
|
(3)
|
(3)
|
|
(4)
|
(3)
|
(7)
|
(14)
|
|
|
Balance at 31 December 2017
|
||||
|
Cost
|
399
|
1
|
83
|
483
|
|
Amortization and impairment losses
|
-
|
-
|
50
|
50
|
|
Carrying amount
|
399
|
1
|
33
|
433
|
|
Change in carrying amount
|
||||
|
- Capital expenditure
|
-
|
4
|
-
|
4
|
|
- Put into operation
|
-
|
(1)
|
1
|
-
|
|
- Exchange difference
|
1
|
-
|
-
|
1
|
|
- Amortization
|
-
|
-
|
(7)
|
(7)
|
|
1
|
3
|
(6)
|
(2)
|
|
|
Balance at 31 December 2018
|
||||
|
Cost
|
400
|
4
|
85
|
489
|
|
Amortization and impairment losses
|
-
|
-
|
58
|
58
|
|
Carrying amount
|
400
|
4
|
27
|
431
|